VanEck Vectors Biotech ETF (BBH) - NYSEARCA
  • Feb. 10, 2014, 12:42 PM
    • Another eight biotechs IPOs raised a combined $502M last week - a new weekly record for the sector amid a rise in the Nasdaq biotech index (IBB) of 70% over the past year. The hot market has companies coming to market at earlier stages of drug development and - in the case of Dicerna Pharmaceuticals (DRNA -2%) which tripled on its first day of trading - without typical restrictions on insiders quickly cashing out.
    • Dicerna has yet to enter clinical trials for its liver disease and cancer drugs which typically means less than a 5% chance of them ever coming to market, according to industry analysts. Moreover, the prospectus says majority shareholders are under no lock-up restrictions. “I’ve never seen an IPO in my career where the existing [majority] shareholders . . . were not subject to a lock-up,” says one expert in the business who notes other firms are inquiring about following the Dicerna example. “A 180-day lock-up is one of those check-the-box provisions for investors," says Skadden Arps' Michael Zeidel.
    • The underwriters defend the arrangement, noting insiders bought about 50% of the IPO, and not having a lock-up should help with trading liquidity.
    • The market may already be stretched - of 14 companies listing so far this year, six are currently below their IPO price.
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Feb. 10, 2014, 12:42 PM | 5 Comments
  • Jan. 28, 2014, 9:12 AM
    • Deutsche's Robyn Karnauskas makes a big call on big-cap biotechs, boosting price targets for Biogen (BIIB) to $415 from $340, Celgene (CELG) to $190 from $170, and Gilead (GILD) to $132 from $95. The $132 PT for Gilead is a new Street high "by a nautical mile," says Notable Calls, and Karnauskas sees upside all the way to $165.
    • "We view large-cap biotech as fundamentally stable yet providing attractive growth," she writes, citing more diversified businesses, pipelines, new product launches, strong balance sheets, and strong free cash flow. "Therefore, we are changing our valuation methodology to 2015 PE multiples from DCF for Gilead, Celgene, and Biogen. Our '15 EPS estimates are higher than consensus and we think near-term franchise success could drive re-rating."
    • GILD +2.7%, CELG +1.3% premarket
    • Related ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Jan. 28, 2014, 9:12 AM | 1 Comment
  • Jan. 27, 2014, 10:52 AM
    • A little bit more air comes out of the previously scorching small-cap biotech names today. Among them: CytRx (CYTR -4.8%), Dyax (DYAX -5.2%), Galena (GALE -9.6%), Novavax (NVAX -9%), Arena (ARNA -6.3%), Synta (SNTA -10.8%), Zogenix (ZGNX -3.5%), Tonix (TNXP -8.4%).
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Jan. 27, 2014, 10:52 AM | 23 Comments
  • Oct. 10, 2013, 11:57 AM
    • Biotechs took a beating in the first three days of this week but they're rallying today, so investors need to decide whether they should be using the dip to buy or the bounce to sell.
    • Citi sees a mixed view for the sector: Given the scarcity of growth stocks in the overall market, the firm expects large-cap biotechs to bounce back but is far less sanguine about small- and mid-caps where valuations are broadly stretched and the Street is overly optimistic of the chances for pipeline success.
    • The firm's favorites include Gilead (GILD +4.7%) and Celgene (CELG +3.5%), and sees compelling risk/reward in Medivation (MDVN +3.9%) and Tesaro (TSRO +5.7%).
    • ETFs: IBB, XBI, FBT, PBE, BBH, BIB, BIS.
    | Oct. 10, 2013, 11:57 AM
  • Oct. 9, 2013, 12:44 PM
    • Biotech stocks suffer a third straight day of heavy losses after recording their worst selloff in two years yesterday, but Bernstein’s Geoffrey Porges says it's not time to panic.
    • Stocks with major uncertain events looming, such as MDVN, or with significant revenue upside already built into valuation, such as PCYC, were among the most severely affected, Porges says, but "nothing changed in the environment to suggest that those events were any more or less likely to have positive outcomes yesterday, or to suggest that revenue potential was any more or less likely to be achieved than was previously expected."
    • Still, investors shouldn’t buy the sector willy-nilly; Porges recommends Celgene (CELG) and Gilead (GILD) among large caps, and notes that less-pricey stocks such as Amgen (AMGN) should hold up better, as should midcaps with earnings and products, such as Alexion (ALXN).
    • ETFs: IBB, XBI, FBT, PBE, BBH, BIB, BIS.
    | Oct. 9, 2013, 12:44 PM | 3 Comments
  • Oct. 9, 2013, 10:52 AM
    • Catalyst Pharmaceuticals (CPRX -8.2%) is sharply lower amid the release of presentation slides ahead of the company's appearance at 12 ET at the BIO Investor Forum.
    • The formerly high-flying biotech sector in general is having another tough day.
    • ETFs: BBH (BBH -3.4%), IBB (IBB -2.9%), XBI (XBI -4.9%).
    | Oct. 9, 2013, 10:52 AM
  • Oct. 8, 2013, 4:25 PM
    • The number of shares aren't specified, but the timing is only slightly off as the high-flying biotech sector slumped badly today. No big deal - Dyax is a near-triple since May.
    • DYAX -3% AH after falling 7.1% in the regular session.
    • ETFs: BBH -4.4%, IBB -4.4%, XBI -5.6%.
    | Oct. 8, 2013, 4:25 PM
  • Sep. 26, 2013, 10:43 AM
    • Cramer says biotech is a safe haven amid the uncertainty emanating from Washington, as pipelines are strong and the sector is not sensitive to the trajectory of the overall economy — this is a "double advantage", he says.
    • Celldex (CLDX +5.3%) — which is part of this week's billion dollar biotech price target bump club courtesy of Leerink and Cantor  — gets a glowing recommendation as Cramer calls the company "just incredible."
    • Other companies getting a name drop: Celgene (CELG +2.4%), Immunogen (IMGN +2%), and Onyx (ONXX).
    • ETFs - IBB, XBI, FBT, PBE, BBH, BIB, BIS
    | Sep. 26, 2013, 10:43 AM
  • May 16, 2013, 1:49 PM

    Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%.

    | May 16, 2013, 1:49 PM | 1 Comment
  • Mar. 28, 2013, 4:24 PM
    Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 
    | Mar. 28, 2013, 4:24 PM | 1 Comment
  • May 14, 2012, 11:45 AM
    Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials - e.g. for Vertex's (VRTX) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly well this year is iShares Nasdaq Biotech (IBB). Others include XBI, FBT and BBH.
    | May 14, 2012, 11:45 AM | 3 Comments
  • Mar. 12, 2012, 12:07 PM
    Shares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector.
    | Mar. 12, 2012, 12:07 PM
  • Sep. 7, 2011, 11:36 AM

    The biotech industry looks ripe for more gains after posting a second consecutive year of profits and seeing M&A activity heat up, says Karvy Global Services. Crunching the numbers reveals 8 stocks with implied upside potential based on quarterly results and analyst recommendations. Picks: HITK, CELG, DNDN, WX, TEVA, ILMN, CRL, BIIB.

    | Sep. 7, 2011, 11:36 AM
  • Aug. 4, 2011, 4:05 PM

    Dendreon (DNDN -67.4%) takes down an entire industry, with the Amex Biotech index falling an astonishing 10.4%. "Biotech risk takers burned on this one might be less risk tolerant going forward," one analyst explains. "The biotech group does work like that, especially for product failures." IBB -7.9%. XBI -9.8%.

    | Aug. 4, 2011, 4:05 PM
  • Jun. 27, 2011, 11:28 AM

    Biofuels developer Verenium (VRNM +8%) announces it has entered into a collaboration with Novus International to develop new enzymes for the animal health and nutrition markets.

    | Jun. 27, 2011, 11:28 AM
  • Jun. 27, 2011, 11:11 AM
    XOMA soars 33% after announcing the discovery of two new classes of fully human monoclonal antibodies at the American Diabetes Association 71st Scientific Sessions in San Diego.
    | Jun. 27, 2011, 11:11 AM
BBH Description
VanEck Vectors Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub